<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; to</title>
	<atom:link href="http://www.tapanray.in/tag/to/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Buying Physicians&#8217; Prescriptions in Cash or Kind: A Global (Dis)Order?</title>
		<link>http://www.tapanray.in/buying-physicians-prescriptions-in-cash-or-kind-a-global-disorder/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=buying-physicians-prescriptions-in-cash-or-kind-a-global-disorder</link>
		<comments>http://www.tapanray.in/buying-physicians-prescriptions-in-cash-or-kind-a-global-disorder/#comments</comments>
		<pubDate>Mon, 09 Sep 2013 00:00:29 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Academic]]></category>
		<category><![CDATA[America]]></category>
		<category><![CDATA[American]]></category>
		<category><![CDATA[Article]]></category>
		<category><![CDATA[barrier]]></category>
		<category><![CDATA[better]]></category>
		<category><![CDATA[Board]]></category>
		<category><![CDATA[breaking]]></category>
		<category><![CDATA[clinic]]></category>
		<category><![CDATA[CME]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[conflict]]></category>
		<category><![CDATA[congressional]]></category>
		<category><![CDATA[Costs]]></category>
		<category><![CDATA[detailing]]></category>
		<category><![CDATA[do]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[educating physicians]]></category>
		<category><![CDATA[education]]></category>
		<category><![CDATA[Family]]></category>
		<category><![CDATA[financial]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[globally]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[gut]]></category>
		<category><![CDATA[hard]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Hidden]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[induce]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[interest]]></category>
		<category><![CDATA[investigation]]></category>
		<category><![CDATA[journal]]></category>
		<category><![CDATA[lesser]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[MCI]]></category>
		<category><![CDATA[Medical]]></category>
		<category><![CDATA[Medical Council. of]]></category>
		<category><![CDATA[medications]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[much travelled]]></category>
		<category><![CDATA[Oregon]]></category>
		<category><![CDATA[Paper]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[Payment]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[phenomenon]]></category>
		<category><![CDATA[Physician]]></category>
		<category><![CDATA[Players]]></category>
		<category><![CDATA[prescriptions]]></category>
		<category><![CDATA[questionable]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[relationship]]></category>
		<category><![CDATA[Representatives]]></category>
		<category><![CDATA[Road]]></category>
		<category><![CDATA[selling]]></category>
		<category><![CDATA[SG&A]]></category>
		<category><![CDATA[shun]]></category>
		<category><![CDATA[states]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[time]]></category>
		<category><![CDATA[to]]></category>
		<category><![CDATA[treatment]]></category>
		<category><![CDATA[UCPMP]]></category>
		<category><![CDATA[United]]></category>
		<category><![CDATA[unnecessary]]></category>
		<category><![CDATA[Up]]></category>
		<category><![CDATA[wrenching]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=2530</guid>
		<description><![CDATA[Recently a European business lobby reportedly raised its voice alleging pharma Multinational Corporations (MNCs) in China have been &#8216;unfairly targeted&#8217; by a string of investigations into bribery and price-fixing cases despite their generally ‘strong legal compliance’ and has suggested that China &#8230; <a href="http://www.tapanray.in/buying-physicians-prescriptions-in-cash-or-kind-a-global-disorder/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/buying-physicians-prescriptions-in-cash-or-kind-a-global-disorder/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Two Paintings on the Same Canvas: &#8216;Truth About Drug Companies&#8217; and &#8216;Protecting Access to Medicines&#8217;</title>
		<link>http://www.tapanray.in/two-paintings-on-the-same-canvas-truth-about-drug-companies-and-protecting-access-to-medicines/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=two-paintings-on-the-same-canvas-truth-about-drug-companies-and-protecting-access-to-medicines</link>
		<comments>http://www.tapanray.in/two-paintings-on-the-same-canvas-truth-about-drug-companies-and-protecting-access-to-medicines/#comments</comments>
		<pubDate>Mon, 13 May 2013 00:00:29 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[about]]></category>
		<category><![CDATA[About It.]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[and]]></category>
		<category><![CDATA[Angell]]></category>
		<category><![CDATA[book]]></category>
		<category><![CDATA[canvas]]></category>
		<category><![CDATA[Chief]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[Deceive]]></category>
		<category><![CDATA[do]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[Editor]]></category>
		<category><![CDATA[England]]></category>
		<category><![CDATA[Forbes]]></category>
		<category><![CDATA[former]]></category>
		<category><![CDATA[foundation]]></category>
		<category><![CDATA[Harvard]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[her]]></category>
		<category><![CDATA[How]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[journal]]></category>
		<category><![CDATA[leading]]></category>
		<category><![CDATA[M.D.faculty]]></category>
		<category><![CDATA[Marcia]]></category>
		<category><![CDATA[Medical]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[NEJM]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[paintings]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[PHFI]]></category>
		<category><![CDATA[President]]></category>
		<category><![CDATA[protecting]]></category>
		<category><![CDATA[public]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Reddy]]></category>
		<category><![CDATA[same]]></category>
		<category><![CDATA[School]]></category>
		<category><![CDATA[Srinath]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>
		<category><![CDATA[TheTruth]]></category>
		<category><![CDATA[they]]></category>
		<category><![CDATA[titled]]></category>
		<category><![CDATA[to]]></category>
		<category><![CDATA[two]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[What to]]></category>
		<category><![CDATA[world’s]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=2280</guid>
		<description><![CDATA[As the saying goes, &#8220;Great people think alike&#8221;, many thought leaders of very high credibility across the globe, seem to think almost in similar lines when it comes to improving access to medicines for a large section of the global &#8230; <a href="http://www.tapanray.in/two-paintings-on-the-same-canvas-truth-about-drug-companies-and-protecting-access-to-medicines/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/two-paintings-on-the-same-canvas-truth-about-drug-companies-and-protecting-access-to-medicines/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>“New drug prices are Astronomical, Unsustainable and Immoral” – Anatomy of Unique Protests</title>
		<link>http://www.tapanray.in/new-drug-prices-are-astronomicalunsustainable-and-immoral-anatomy-of-unique-protests/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=new-drug-prices-are-astronomicalunsustainable-and-immoral-anatomy-of-unique-protests</link>
		<comments>http://www.tapanray.in/new-drug-prices-are-astronomicalunsustainable-and-immoral-anatomy-of-unique-protests/#comments</comments>
		<pubDate>Mon, 06 May 2013 00:00:37 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[ACTH]]></category>
		<category><![CDATA[America]]></category>
		<category><![CDATA[anatomy]]></category>
		<category><![CDATA[astonishingly]]></category>
		<category><![CDATA[astronomical]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[center]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[Conference]]></category>
		<category><![CDATA[Cowen]]></category>
		<category><![CDATA[diseases]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[dutch]]></category>
		<category><![CDATA[economics]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[European]]></category>
		<category><![CDATA[expensive]]></category>
		<category><![CDATA[HBR]]></category>
		<category><![CDATA[Hunter]]></category>
		<category><![CDATA[immoral]]></category>
		<category><![CDATA[Index]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Ireland]]></category>
		<category><![CDATA[kettering]]></category>
		<category><![CDATA[London]]></category>
		<category><![CDATA[LSE]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[memorial]]></category>
		<category><![CDATA[most]]></category>
		<category><![CDATA[Netherlands]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[NewYork]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[Orphan]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[pompe]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[profiteering]]></category>
		<category><![CDATA[protests]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[rare]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[researchers]]></category>
		<category><![CDATA[School]]></category>
		<category><![CDATA[Sloan]]></category>
		<category><![CDATA[Syndrome]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[therapeutic]]></category>
		<category><![CDATA[to]]></category>
		<category><![CDATA[Trial]]></category>
		<category><![CDATA[UK]]></category>
		<category><![CDATA[Union]]></category>
		<category><![CDATA[unique]]></category>
		<category><![CDATA[unsustainable]]></category>
		<category><![CDATA[upsurge]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[USA]]></category>
		<category><![CDATA[WHO]]></category>
		<category><![CDATA[World]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=2347</guid>
		<description><![CDATA[Yes. The quoted sentiment captured in the headline was reportedly voiced recently by many cancer specialists, including researchers and that too in the heartland of pharmaceutical innovation of the world– the United States of America. These specialist doctors argued: “High &#8230; <a href="http://www.tapanray.in/new-drug-prices-are-astronomicalunsustainable-and-immoral-anatomy-of-unique-protests/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/new-drug-prices-are-astronomicalunsustainable-and-immoral-anatomy-of-unique-protests/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>The Ghost Keeps Haunting: NCD Dogs Cancer in &#8216;Compulsory License&#8217; Debate of India</title>
		<link>http://www.tapanray.in/the-ghost-keeps-haunting-ncd-dogs-cancer-in-compulsory-license-debate-of-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=the-ghost-keeps-haunting-ncd-dogs-cancer-in-compulsory-license-debate-of-india</link>
		<comments>http://www.tapanray.in/the-ghost-keeps-haunting-ncd-dogs-cancer-in-compulsory-license-debate-of-india/#comments</comments>
		<pubDate>Mon, 11 Mar 2013 00:00:12 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[agreement]]></category>
		<category><![CDATA[biologics]]></category>
		<category><![CDATA[biosimilar]]></category>
		<category><![CDATA[breast]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[chemotherapy]]></category>
		<category><![CDATA[Citizens']]></category>
		<category><![CDATA[CL]]></category>
		<category><![CDATA[collective]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[Compulsory]]></category>
		<category><![CDATA[Dasatinib]]></category>
		<category><![CDATA[debate]]></category>
		<category><![CDATA[DIPP]]></category>
		<category><![CDATA[dogs]]></category>
		<category><![CDATA[DoP]]></category>
		<category><![CDATA[ghost]]></category>
		<category><![CDATA[haunting]]></category>
		<category><![CDATA[Herceptin]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovator]]></category>
		<category><![CDATA[IP]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[Ixabepilone]]></category>
		<category><![CDATA[keeps]]></category>
		<category><![CDATA[Legal]]></category>
		<category><![CDATA[leukemia]]></category>
		<category><![CDATA[License]]></category>
		<category><![CDATA[Minister]]></category>
		<category><![CDATA[NCD]]></category>
		<category><![CDATA[negotiation]]></category>
		<category><![CDATA[patented]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[PM]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Prime]]></category>
		<category><![CDATA[products]]></category>
		<category><![CDATA[protein]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Roche]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[to]]></category>
		<category><![CDATA[Trastuzumab]]></category>
		<category><![CDATA[treat]]></category>
		<category><![CDATA[TRIPS]]></category>
		<category><![CDATA[UN]]></category>
		<category><![CDATA[used]]></category>
		<category><![CDATA[WHO]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=2037</guid>
		<description><![CDATA[In November 2012, as a part of the ‘Campaign for Affordable Trastuzumab’ for the treatment of breast cancer, a citizens’ collective, reportedly sent an ‘Open Letter’ signed by around 200 cancer survivors, women’s groups, human rights and health rights campaigns &#8230; <a href="http://www.tapanray.in/the-ghost-keeps-haunting-ncd-dogs-cancer-in-compulsory-license-debate-of-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/the-ghost-keeps-haunting-ncd-dogs-cancer-in-compulsory-license-debate-of-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Obama Wins: ‘Obamacare’ stays on course… and what it means to India?</title>
		<link>http://www.tapanray.in/obama-wins-obamacare-stays-on-course-and-what-it-means-to-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=obama-wins-obamacare-stays-on-course-and-what-it-means-to-india</link>
		<comments>http://www.tapanray.in/obama-wins-obamacare-stays-on-course-and-what-it-means-to-india/#comments</comments>
		<pubDate>Mon, 12 Nov 2012 00:00:46 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[abbott]]></category>
		<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[Compulsory Licensing]]></category>
		<category><![CDATA[Counterfeit]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Ethical Marketing]]></category>
		<category><![CDATA[FDI]]></category>
		<category><![CDATA[glaxo]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Hospital]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[it]]></category>
		<category><![CDATA[kopran]]></category>
		<category><![CDATA[Legal]]></category>
		<category><![CDATA[means]]></category>
		<category><![CDATA[Medical Diagnostics]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[Neutraceutical]]></category>
		<category><![CDATA[NPPA]]></category>
		<category><![CDATA[Obama]]></category>
		<category><![CDATA[Obamacare]]></category>
		<category><![CDATA[on course]]></category>
		<category><![CDATA[OPPI]]></category>
		<category><![CDATA[Patents]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[PHC]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[RDP]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[Research & Development]]></category>
		<category><![CDATA[sami]]></category>
		<category><![CDATA[Spurious]]></category>
		<category><![CDATA[stakeholders]]></category>
		<category><![CDATA[stays]]></category>
		<category><![CDATA[strategy]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[therapeutic]]></category>
		<category><![CDATA[to]]></category>
		<category><![CDATA[Trials]]></category>
		<category><![CDATA[what]]></category>
		<category><![CDATA[Wins]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=1069</guid>
		<description><![CDATA[Re-election of President Barrack Obama for another four year term, no doubt, sends a clear signal to all concerned that full implementation of the ‘Patient Protection and Affordable Care Act’ of America, which is also known to many as ‘Obamacare’, &#8230; <a href="http://www.tapanray.in/obama-wins-obamacare-stays-on-course-and-what-it-means-to-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/obama-wins-obamacare-stays-on-course-and-what-it-means-to-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>India: Too Enticing a Pharma Market to Ignore by the Global Players despite unhappiness</title>
		<link>http://www.tapanray.in/india-too-enticing-a-pharma-market-to-ignore-by-the-global-players-despite-unhappiness/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=india-too-enticing-a-pharma-market-to-ignore-by-the-global-players-despite-unhappiness</link>
		<comments>http://www.tapanray.in/india-too-enticing-a-pharma-market-to-ignore-by-the-global-players-despite-unhappiness/#comments</comments>
		<pubDate>Mon, 22 Oct 2012 00:00:36 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[abbott]]></category>
		<category><![CDATA[Biotech]]></category>
		<category><![CDATA[by]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[Compulsory Licensing]]></category>
		<category><![CDATA[Counterfeit]]></category>
		<category><![CDATA[despite]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Enticing]]></category>
		<category><![CDATA[Ethical Marketing]]></category>
		<category><![CDATA[FDI]]></category>
		<category><![CDATA[glaxo]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Hospital]]></category>
		<category><![CDATA[Ignore]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[kopran]]></category>
		<category><![CDATA[Legal]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[Medical Diagnostics]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[Neutraceutical]]></category>
		<category><![CDATA[NPPA]]></category>
		<category><![CDATA[OPPI]]></category>
		<category><![CDATA[Patents]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[PHC]]></category>
		<category><![CDATA[Players]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[RDP]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[Research & Development]]></category>
		<category><![CDATA[sami]]></category>
		<category><![CDATA[Spurious]]></category>
		<category><![CDATA[stakeholders]]></category>
		<category><![CDATA[strategy]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[the]]></category>
		<category><![CDATA[therapeutic]]></category>
		<category><![CDATA[to]]></category>
		<category><![CDATA[Too]]></category>
		<category><![CDATA[Trials]]></category>
		<category><![CDATA[unhappiness]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=1078</guid>
		<description><![CDATA[A White-Paper, titled “Emerging Markets Today and Tomorrow: Insights on Healthcare, Pharmaceuticals and Future Trends in the BRIC Landscape”, released by a global technology and services company specializing in healthcare, Cegedim, in June, 2012 highlighted that 20 to 30 percent &#8230; <a href="http://www.tapanray.in/india-too-enticing-a-pharma-market-to-ignore-by-the-global-players-despite-unhappiness/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/india-too-enticing-a-pharma-market-to-ignore-by-the-global-players-despite-unhappiness/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>“Bad Pharma: How Drug Companies Mislead Doctors and Harm Patients”: Exploring the book to be released in the Indian context</title>
		<link>http://www.tapanray.in/bad-pharma-how-drug-companies-mislead-doctors-and-harm-patients-exploring-the-book-to-be-released-in-the-indian-context/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=bad-pharma-how-drug-companies-mislead-doctors-and-harm-patients-exploring-the-book-to-be-released-in-the-indian-context</link>
		<comments>http://www.tapanray.in/bad-pharma-how-drug-companies-mislead-doctors-and-harm-patients-exploring-the-book-to-be-released-in-the-indian-context/#comments</comments>
		<pubDate>Mon, 15 Oct 2012 00:00:14 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[abbott]]></category>
		<category><![CDATA[and]]></category>
		<category><![CDATA[Bad]]></category>
		<category><![CDATA[be]]></category>
		<category><![CDATA[Biotech]]></category>
		<category><![CDATA[book]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[Compulsory Licensing]]></category>
		<category><![CDATA[context]]></category>
		<category><![CDATA[Counterfeit]]></category>
		<category><![CDATA[doctors]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Ethical Marketing]]></category>
		<category><![CDATA[Exploring]]></category>
		<category><![CDATA[FDI]]></category>
		<category><![CDATA[glaxo]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Harm]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Hospital]]></category>
		<category><![CDATA[How]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[kopran]]></category>
		<category><![CDATA[Legal]]></category>
		<category><![CDATA[Medical Diagnostics]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[Mislead]]></category>
		<category><![CDATA[Neutraceutical]]></category>
		<category><![CDATA[NPPA]]></category>
		<category><![CDATA[OPPI]]></category>
		<category><![CDATA[Patents]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[PHC]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[RDP]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[released]]></category>
		<category><![CDATA[Research & Development]]></category>
		<category><![CDATA[sami]]></category>
		<category><![CDATA[Spurious]]></category>
		<category><![CDATA[stakeholders]]></category>
		<category><![CDATA[strategy]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[the]]></category>
		<category><![CDATA[therapeutic]]></category>
		<category><![CDATA[to]]></category>
		<category><![CDATA[Trials]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=1081</guid>
		<description><![CDATA[The title of today’s article could make some of the readers uncomfortable and angry, just as what I experienced while writing the same, being a long time follower and student of the pharmaceutical industry, both global and local. Ethical business &#8230; <a href="http://www.tapanray.in/bad-pharma-how-drug-companies-mislead-doctors-and-harm-patients-exploring-the-book-to-be-released-in-the-indian-context/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/bad-pharma-how-drug-companies-mislead-doctors-and-harm-patients-exploring-the-book-to-be-released-in-the-indian-context/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Pharma industry requires striking a right balance between ethical obligations to shareholders and ethical obligations to patients</title>
		<link>http://www.tapanray.in/pharma-industry-requires-striking-a-right-balance-between-ethical-obligations-to-shareholders-and-ethical-obligations-to-patients/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=pharma-industry-requires-striking-a-right-balance-between-ethical-obligations-to-shareholders-and-ethical-obligations-to-patients</link>
		<comments>http://www.tapanray.in/pharma-industry-requires-striking-a-right-balance-between-ethical-obligations-to-shareholders-and-ethical-obligations-to-patients/#comments</comments>
		<pubDate>Mon, 24 Sep 2012 00:00:29 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[a]]></category>
		<category><![CDATA[abbott]]></category>
		<category><![CDATA[and]]></category>
		<category><![CDATA[balance]]></category>
		<category><![CDATA[between]]></category>
		<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[Compulsory Licensing]]></category>
		<category><![CDATA[Counterfeit]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[ethical]]></category>
		<category><![CDATA[Ethical Marketing]]></category>
		<category><![CDATA[FDI]]></category>
		<category><![CDATA[glaxo]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Hospital]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[kopran]]></category>
		<category><![CDATA[Legal]]></category>
		<category><![CDATA[Medical Diagnostics]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[Neutraceutical]]></category>
		<category><![CDATA[NPPA]]></category>
		<category><![CDATA[obligations]]></category>
		<category><![CDATA[OPPI]]></category>
		<category><![CDATA[Patents]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[PHC]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[RDP]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[requires]]></category>
		<category><![CDATA[Research & Development]]></category>
		<category><![CDATA[right]]></category>
		<category><![CDATA[sami]]></category>
		<category><![CDATA[shareholders]]></category>
		<category><![CDATA[Spurious]]></category>
		<category><![CDATA[stakeholders]]></category>
		<category><![CDATA[strategy]]></category>
		<category><![CDATA[striking]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[therapeutic]]></category>
		<category><![CDATA[to]]></category>
		<category><![CDATA[Trials]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=6</guid>
		<description><![CDATA[On September 15, 2012, while delivering his keynote address in a pharmaceutical industry function, Dr. Sam Pitroda, the Chicago based Indian, creator of the telecom revolution in India and the Advisor to the Prime Minister on Public Information, Infrastructure &#38; &#8230; <a href="http://www.tapanray.in/pharma-industry-requires-striking-a-right-balance-between-ethical-obligations-to-shareholders-and-ethical-obligations-to-patients/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/pharma-industry-requires-striking-a-right-balance-between-ethical-obligations-to-shareholders-and-ethical-obligations-to-patients/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Replication of ‘Old Paradigm’ of the developed pharmaceutical markets is unlikely to yield results in the evolving new paradigm of India</title>
		<link>http://www.tapanray.in/replication-of-old-paradigm-of-the-developed-pharmaceutical-markets-is-unlikely-to-yield-results-in-the-evolving-new-paradigm-of-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=replication-of-old-paradigm-of-the-developed-pharmaceutical-markets-is-unlikely-to-yield-results-in-the-evolving-new-paradigm-of-india</link>
		<comments>http://www.tapanray.in/replication-of-old-paradigm-of-the-developed-pharmaceutical-markets-is-unlikely-to-yield-results-in-the-evolving-new-paradigm-of-india/#comments</comments>
		<pubDate>Mon, 03 Sep 2012 00:00:11 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[abbott]]></category>
		<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[Compulsory Licensing]]></category>
		<category><![CDATA[Counterfeit]]></category>
		<category><![CDATA[developed]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Ethical Marketing]]></category>
		<category><![CDATA[evolving]]></category>
		<category><![CDATA[FDI]]></category>
		<category><![CDATA[glaxo]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Hospital]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[is]]></category>
		<category><![CDATA[kopran]]></category>
		<category><![CDATA[Legal]]></category>
		<category><![CDATA[markets]]></category>
		<category><![CDATA[Medical Diagnostics]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[Neutraceutical]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[NPPA]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[Old]]></category>
		<category><![CDATA[OPPI]]></category>
		<category><![CDATA[paradigm]]></category>
		<category><![CDATA[Patents]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[PHC]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[RDP]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[Replication]]></category>
		<category><![CDATA[Research & Development]]></category>
		<category><![CDATA[results]]></category>
		<category><![CDATA[sami]]></category>
		<category><![CDATA[Spurious]]></category>
		<category><![CDATA[stakeholders]]></category>
		<category><![CDATA[strategy]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[the]]></category>
		<category><![CDATA[therapeutic]]></category>
		<category><![CDATA[to]]></category>
		<category><![CDATA[Trials]]></category>
		<category><![CDATA[unlikely]]></category>
		<category><![CDATA[yield]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=40</guid>
		<description><![CDATA[“Health leaps out of science and draws nourishment from the society around it” - Gunnar Myrdal (Swedish Nobel Laureate Economist) The success concoction of the global pharmaceutical industry for India, by and large, still remains to be sustained attempts in &#8230; <a href="http://www.tapanray.in/replication-of-old-paradigm-of-the-developed-pharmaceutical-markets-is-unlikely-to-yield-results-in-the-evolving-new-paradigm-of-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/replication-of-old-paradigm-of-the-developed-pharmaceutical-markets-is-unlikely-to-yield-results-in-the-evolving-new-paradigm-of-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Should India allow use of Compulsory License as a common tool to improve access to medicines?</title>
		<link>http://www.tapanray.in/should-india-allow-use-of-compulsory-license-as-a-common-tool-to-improve-access-to-medicines/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=should-india-allow-use-of-compulsory-license-as-a-common-tool-to-improve-access-to-medicines</link>
		<comments>http://www.tapanray.in/should-india-allow-use-of-compulsory-license-as-a-common-tool-to-improve-access-to-medicines/#comments</comments>
		<pubDate>Mon, 20 Aug 2012 00:00:18 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[abbott]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[allow]]></category>
		<category><![CDATA[as]]></category>
		<category><![CDATA[Biotech]]></category>
		<category><![CDATA[CL]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[common]]></category>
		<category><![CDATA[Compulsory]]></category>
		<category><![CDATA[Compulsory Licensing]]></category>
		<category><![CDATA[Counterfeit]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Ethical Marketing]]></category>
		<category><![CDATA[FDI]]></category>
		<category><![CDATA[glaxo]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Hospital]]></category>
		<category><![CDATA[improve]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[kopran]]></category>
		<category><![CDATA[Legal]]></category>
		<category><![CDATA[License]]></category>
		<category><![CDATA[Medical Diagnostics]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[Neutraceutical]]></category>
		<category><![CDATA[NPPA]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[OPPI]]></category>
		<category><![CDATA[Patents]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[PHC]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[RDP]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[Research & Development]]></category>
		<category><![CDATA[sami]]></category>
		<category><![CDATA[Should]]></category>
		<category><![CDATA[Spurious]]></category>
		<category><![CDATA[stakeholders]]></category>
		<category><![CDATA[strategy]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[therapeutic]]></category>
		<category><![CDATA[to]]></category>
		<category><![CDATA[tool]]></category>
		<category><![CDATA[Trials]]></category>
		<category><![CDATA[use]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=48</guid>
		<description><![CDATA[Compulsory License (CL) is generally considered a very important provision in the Patent Act of a country to protect public health interest not only by the governments, but also by a large number of experts across the globe and the &#8230; <a href="http://www.tapanray.in/should-india-allow-use-of-compulsory-license-as-a-common-tool-to-improve-access-to-medicines/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/should-india-allow-use-of-compulsory-license-as-a-common-tool-to-improve-access-to-medicines/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
